By admin 
The sheer scale of public participation in federal rulemaking has reached a breaking point, exemplified by the SEC’s recent proposal to eliminate the requirement for quarterly financial reports. To date, the agency has received over 200,000 public comments, a staggering figure that dwarfs typical regulatory feedback cycles. While many of these submissions appear to be the product of automated campaigns and interest-group templates, the volume reflects a deep-seated anxiety regarding corporate accountability. Proponents of the shift, including some corporate executives and trade groups, argue that quarterly reporting fosters "short-termism," forcing companies to prioritize immediate stock performance over long-term strategic investment. However, for the health care sector—where massive pharmaceutical companies and hospital conglomerates operate with complex, often opaque financial structures—the removal of these disclosures could obscure critical data on drug pricing, profit margins, and executive compensation.
As the SEC sifts through this unprecedented mountain of paperwork, CMS is executing a more direct assault on hospital revenues through its latest outpatient prospective payment system (OPPS) rule. The most immediate and consequential policy change involves a aggressive reduction in payments for drugs acquired through the 340B discount program. Established in 1992, the 340B program was designed to allow safety-net hospitals to stretch scarce federal resources by purchasing outpatient drugs at significant discounts from manufacturers. For decades, hospitals have benefited from the "spread"—the difference between the heavily discounted price they pay for a drug and the higher reimbursement rate they receive from Medicare. CMS’s latest move to slash these reimbursements represents a fundamental shift in how the government views the program, moving away from a subsidy model toward one that mirrors the actual cost of acquisition.
The hospital industry has reacted with predictable alarm, characterizing the 340B cuts as a direct threat to the viability of rural and urban safety-net facilities. Industry advocates argue that the profits generated from the 340B program are not mere windfalls but are essential to funding uncompensated care, oncology clinics, and community outreach programs that would otherwise be unsustainable. However, critics of the program, including pharmaceutical manufacturers and some fiscal hawks, point to the lack of transparency in how hospitals utilize these savings. They argue that the program has expanded far beyond its original intent, incentivizing hospitals to acquire independent physician practices and shift care to more expensive outpatient settings simply to capture the 340B spread.
Beyond the 340B cuts, CMS has subtly doubled down on a policy that hospitals arguably loathe even more: site-neutral payments. The concept of site-neutrality is deceptively simple—Medicare should pay the same amount for a service regardless of where it is performed. Currently, if a patient receives a steroid injection or a basic diagnostic test in a hospital-owned outpatient department, Medicare often pays significantly more than it would if the same service were provided in an independent physician’s office. CMS has long sought to close this gap to reduce costs for the Medicare Trust Fund and lower out-of-pocket expenses for beneficiaries.
The "Site-Neutral Milk Hotel" of regulatory hurdles—as some insiders have wryly dubbed the current policy environment—is becoming a permanent fixture of the hospital landscape. By expanding the list of services subject to site-neutral rates, CMS is effectively penalizing the hospital-acquisition model that has dominated the last decade of health care consolidation. For years, health systems have aggressively purchased independent clinics and rebranded them as "hospital outpatient departments" (HOPDs) to take advantage of higher facility fees. The latest CMS rules signal that the agency is no longer willing to subsidize this trend, much to the chagrin of organizations like the American Hospital Association (AHA).
The AHA and other industry groups contend that hospital outpatient departments have higher overhead costs than independent offices, driven by strict regulatory requirements, the need to maintain 24/7 emergency capabilities, and the obligation to treat all patients regardless of their ability to pay. They argue that site-neutrality is a blunt instrument that fails to account for the "complexity of the patient" and the "mission-driven costs" of a hospital system. Despite these protestations, the momentum toward site-neutrality appears unstoppable, as it remains one of the few policy areas with broad bipartisan support in a polarized Washington. Both the Trump and Biden administrations, as well as various congressional committees, have identified site-neutrality as a primary lever for controlling health care spending.
The financial pressure on hospitals is further exacerbated by the broader economic climate of 2026. Labor costs remain at historic highs following years of nursing shortages and burnout, while the cost of medical supplies and technology continues to outpace general inflation. For many systems, the combination of 340B cuts and expanded site-neutrality could be the tipping point that moves their operating margins into the red. This is particularly true for mid-sized systems that lack the scale to negotiate more favorable rates with private insurers or the diversified revenue streams of larger, multi-state conglomerates.
Furthermore, the opaque nature of prescription drug benefits continues to be a focal point of regulatory scrutiny. While CMS focuses on hospital payments, the role of Pharmacy Benefit Managers (PBMs) is also under the microscope. The interplay between 340B discounts, PBM rebates, and Medicare reimbursement creates a convoluted web of incentives that often results in higher costs for patients at the pharmacy counter. Bob Herman’s reporting has consistently highlighted how these hidden financial flows dictate the quality and accessibility of care, and the current newsletter underscores the fact that the "business" of health care is increasingly a battle over data and transparency.
The 200,000 comments submitted to the SEC regarding quarterly reporting are not just a logistical nightmare for regulators; they represent a fundamental debate over the soul of corporate governance in the United States. If quarterly reports are eliminated, the public may lose its most consistent window into the financial health of the companies that provide their life-saving medications and manage their health insurance plans. In an industry as vital as health care, the trade-off between "long-term strategic focus" and "immediate public accountability" is fraught with risk. Without frequent disclosures, the ability of journalists, researchers, and policymakers to identify predatory pricing or systemic financial instability would be severely curtailed.
As we look toward the remainder of 2026, the tension between the providers of care and the payers of care will only intensify. CMS is signaling that it will continue to use its rulemaking power to drive efficiency, even if it means disrupting the traditional hospital business model. Hospitals, in turn, are likely to escalate their legal challenges, taking their fight against 340B cuts and site-neutrality to the Supreme Court if necessary. The outcome of these battles will determine not just the profitability of health care corporations, but the very structure of the American medical delivery system.
For the readers of STAT’s Health Care Inc., the takeaway is clear: the era of easy revenue through billing arbitrage is coming to a close. Whether through the direct cutting of drug discounts or the leveling of payment fields across different care sites, the federal government is tightening the reins. The massive public response to the SEC’s transparency proposals suggests that the public is watching more closely than ever, even if the sheer volume of their voices threatens to clog the machinery of government. In this high-stakes environment, the ability to navigate complex regulatory shifts while maintaining a commitment to patient care will be the ultimate test for health care executives and policymakers alike. The "site-neutral" future is no longer a distant possibility; it is a burgeoning reality that will reshape the economics of medicine for decades to come.
